Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.

Diabetes Obes Metab · 2020 · PMC6916612 · PMID 31468659

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Conversely, aleglitazar showed a trend for a decreased risk of hospitalization for heart failure (HR: 0.78, 95% CI: 0.57–1.06) among patients without using clopidogrel.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.